- Home
- REPL vs SCSC Comparison
REPL vs SCSC Comparison
Compare REPL & SCSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- SCSC
- Stock Information
- Founded
- REPL 2015
- SCSC 1992
- Country
- REPL United States
- SCSC United States
- Employees
- REPL 331
- SCSC N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- SCSC Retail: Computer Software & Peripheral Equipment
- Sector
- REPL Health Care
- SCSC Technology
- Exchange
- REPL Nasdaq
- SCSC Nasdaq
- Market Cap
- REPL 1.1B
- SCSC 892.1M
- IPO Year
- REPL 2018
- SCSC 1994
- Fundamental
- Price
- REPL $13.98
- SCSC $37.20
- Analyst Decision
- REPL Strong Buy
- SCSC Hold
- Analyst Count
- REPL 6
- SCSC 1
- Target Price
- REPL $19.83
- SCSC N/A
- AVG Volume (30 Days)
- REPL 610.9K
- SCSC 227.9K
- Earning Date
- REPL 02-12-2025
- SCSC 01-30-2025
- Dividend Yield
- REPL N/A
- SCSC N/A
- EPS Growth
- REPL N/A
- SCSC N/A
- EPS
- REPL N/A
- SCSC 2.54
- Revenue
- REPL N/A
- SCSC $3,021,788,000.00
- Revenue This Year
- REPL N/A
- SCSC N/A
- Revenue Next Year
- REPL $1,065.54
- SCSC $6.58
- P/E Ratio
- REPL N/A
- SCSC $14.91
- Revenue Growth
- REPL N/A
- SCSC N/A
- 52 Week Low
- REPL $4.92
- SCSC $36.63
- 52 Week High
- REPL $17.00
- SCSC $53.90
- Technical
- Relative Strength Index (RSI)
- REPL 55.54
- SCSC 25.01
- Support Level
- REPL $13.40
- SCSC $36.71
- Resistance Level
- REPL $14.59
- SCSC $37.81
- Average True Range (ATR)
- REPL 0.84
- SCSC 1.17
- MACD
- REPL -0.02
- SCSC -0.07
- Stochastic Oscillator
- REPL 66.52
- SCSC 12.45
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
About SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.